Clinical course and prognostic factors following bone recurrence from breast cancer

British Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 336-340

  Coleman, R E ^a   Smith, P ^b   Rubens, R D ^b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PREDNISOLONE; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; DISEASE COURSE; FEMALE; HUMAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 0031964897     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.52     Document Type: Article

References (17)

1. Bloom HJG and Richardson WW (1957) Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 2: 359-377
2. Body J-J, Coleman RE and Piccart M (1996) Use of bisphosphonates in cancer patients. Cancer Treat Rev 22: 265-287
3. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM and Ratcliffe JG (1992) Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 28: 690-692
4. Coleman RE and Rubens RD (1987) The clinical course of bone metastases. Br J Cancer 55: 61-66
5. Conte PF, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G and Ford JM (1996) Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial. J Clin Oncol 14: 2552-2559
6. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187-220
7. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M and Reitsma D (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med 335: 1785-1791
8. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. Am Stat Assoc J 53: 457-481
9. King RJB, Redgrave R, Hayward JL, Millis RR and Rubens RD (1979) The measurement of receptors for oestradiol and progesterone in human breast cancers. In Steroid Receptor Assays In Breast Tumours: Methodological and clinical aspects, King RJB. (ed.), p. 55, Alpha Omega: Cardiff
10. Koenders PG, Beex LVAM, Langens R, Kloppenborg PWC, Smals AGH, Benraad J for the Breast Cancer Study Group (1991) Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. Breast Cancer Res Treat 18: 27-32
11. Lipton A, Theriault R, Leff R, Gluck S, Stewart J, Costello S, Simeone J, Seaman J, Knight R, Heffernan M and Reitsma D (1997) Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia) infusions. ASCO Proc 16: 152a
12. Paterson AHG, Powles TJ, Kanis JA, McClosky E, Hanson J and Ashley S (1993) Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
13. Peto R, Pike MC and Armitage P (1977) Design and analysis of clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39
14. Purohit OP, Anthony C, Radstone CR, Owen J and Coleman RE (1994) High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70: 554-558
15. Scher HI and Yagoda A (1987) Bone metastases: Pathogenesis, treatment and rationale for use of resorption inhibitors. Am J Med 82 (suppl. 2a): 6-27
16. Vargas SJ, Gillespie MT, Powell GJ, Southby GJ, Donks JA, Moseley JM and Martin TJ (1992) Localisation of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridisation. J Bone Miner Res 7: 971-979
17. Vinholes J, Coleman RE and Eastell R (1996) Effects of bone metastases on bone metabolism. Implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22: 289-331